Comparison of Mitral Valve Replacement and Repair for Degenerative Mitral Regurgitation: a Meta-analysis and Implications for Transcatheter Mitral Procedures.


Journal

Current cardiology reports
ISSN: 1534-3170
Titre abrégé: Curr Cardiol Rep
Pays: United States
ID NLM: 100888969

Informations de publication

Date de publication:
09 07 2020
Historique:
entrez: 11 7 2020
pubmed: 11 7 2020
medline: 28 1 2021
Statut: epublish

Résumé

Surgical mitral valve repair is considered superior to replacement to treat primary mitral regurgitation. However, the heterogeneity of cohorts and the lack of consideration of confounding in the published literature raise potential biases. The aim of this study was to pool all available matched data comparing outcomes of mitral valve repair and replacement in the setting of primary mitral regurgitation. We searched Medline, Embase and the Cochrane Library Central Register of Controlled Trials to identify propensity-matched studies or reports with multivariable adjustment comparing repair and replacement in patients with primary mitral regurgitation. The primary outcome was all-cause mortality. DerSimonian and Laird random effects were used to perform the meta-analysis. Eight observational studies were selected including 4599 patients (3064 mitral repairs and 1535 replacements). Mean age ranged from 62 to 69 years, and the mean follow-up duration ranged between 3 and 9 years. Replacement was associated with an increased risk of long-term all-cause mortality compared to repair (HR of 1.68, 95% confidence interval 1.35-2.09, p < 0.001, τ

Identifiants

pubmed: 32648008
doi: 10.1007/s11886-020-01333-x
pii: 10.1007/s11886-020-01333-x
doi:

Types de publication

Journal Article Meta-Analysis Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

79

Auteurs

P Overtchouk (P)

Structural Valve Program, CHRU-Lille, Lille, France.

W Ben-Ali (W)

Structural Valve Program, CHRU-Lille, Lille, France.
Department of Cardiac Surgery, Montreal Heart Institute, Montreal, QC, Canada.

B Prendergast (B)

Department of Cardiology, St Thomas' Hospital, London, UK.

L Conradi (L)

Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany.

R Hahn (R)

Division of Cardiology, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA.

J Granada (J)

Cardiovascular Research Foundation, CRF Skirball Center for Innovation, Columbia University Medical Center, New York, NY, USA.

T Modine (T)

Structural Valve Program, CHRU-Lille, Lille, France. thomas.modine@chru-lille.fr.
Interventional Cardiology and Cardiovascular Surgery, Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille), 2 Avenue Oscar Lambret, 59037, Lille, France. thomas.modine@chru-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH